AFG3L2 and neoplasm: Results showed blocking the CRABP2–AFG3L2–SLC25A39 interaction led to reduced tumor weight and size (Figure 6J,K; Figure S6B, Supporting Information), with consistent results obtained from in vitro experiments (Figure S6C,D, Supporting Information).